- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01453062
Phase IV Observational Study in Chronic Lymphocytic Leukemia
Phase IV Observational Study in Chronic Lymphocytic Leukemia Patients Receiving Ofatumumab in the European Union
B-cell chronic lymphocytic leukemia (CLL) is a subtype of mature peripheral B-cell neoplasms, characterized by the accumulation of circulating malignant lymphocytes that typically express cell surface markers CD5, CD20, and CD23. It is the most common type of leukemia in adults in Western Europe and in the US. The median age at diagnosis is 65-70 years, with a male to female ratio of 2:1. Initially, most patients present with asymptomatic lymphocytosis and do not need cytoreductive therapy. Patients with active disease are characterized by a lymphocyte doubling time of less than 6 months, or progressive, even massive lymphadenopathy, hepatosplenomegaly, anemia and thrombocytopenia. Constitutional symptoms such as fever, night sweats, unintended weight loss, and extreme fatigue are common in advanced disease and can significantly impact quality of life. CLL also causes relative immunosuppression that increases the risk of infections that are ultimately the major cause of death in this patient population. Median survival at diagnosis ranges from 5 to 20+ years depending on risk factors, but is only 6 to 14 months for patients with CLL refractory to available therapies.
Arzerra (ofatumumab) is a human monoclonal antibody (IgG1) that binds specifically to a distinct epitope encompassing both the small and large extracellular loops of the CD20 molecule. The CD20 molecule is a transmembrane phosphoprotein expressed on B lymphocytes from the pre-B to mature B lymphocyte stage and on B-cell tumors.
Arzerra is designated as an orphan medicinal product in the European Union (EU) for treatment of chronic lymphocytic leukemia. The Committee for Orphan Medicinal Products (COMP) concluded that chronic lymphocytic leukemia was estimated to be affecting approximately 3.5 in 10,000 persons in the Community at the time the application was made (June 2008) and that the condition is chronically debilitating and life-threatening, in particular due to poor long-term survival in high-risk patients.
Arzerra was given a conditional approval in the EU on April 19, 2010. The approved indication in the EU for the product is treatment of CLL in patients refractory to fludarabine and alemtuzumab. A specific obligation for this conditional approval was an agreement by GSK to conduct a post-marketing observational study in CLL patients receiving Arzerra. The data from this study is intended to enhance the evidence of the safety and efficacy of Arzerra as it is used in clinical practice, and once final data are available, together with results of a second specific obligation study, will support the transition from conditional to a full approval of Arzerra in the EU.
The objective of this observational study is to provide additional data to confirm the safety profile and efficacy of Arzerra for CLL patients treated in clinical practice.
Particular data of interest are: co-morbidities (specific chronic disease diagnoses), concomitant medications, disease (CLL) characteristics, prior treatment regimens, adverse events, reasons for discontinuation of Arzerra therapy, Arzerra response, progression free survival, and overall survival.
This is an observational, non-interventional, medical record review study in CLL patients. A total of 100 patients with CLL who have previously received Arzerra, whether alive or deceased, and have either completed the full course of Arzerra therapy or discontinued treatment early will be eligible to participate in the study. Centers across Europe who are members and non members of the European Research Initiative of CLL (ERIC) and treat CLL patients will participate in the study.
CLL patients newly initiating Arzerra who are still undergoing the treatment phase and patients having been treated with Arzerra in phase II or phase III clinical trials will be excluded.
For patients who have completed approximately 1 year or more of follow up since Arzerra initiation, data on response to Arzerra, adverse events during treatment and subsequent to treatment, patient status, progression free survival and overall survival covering the period up to approximately one-year post-drug initiation will be collected. For patients who have not completed approximately l year of follow-up since Arzerra initiation, including those who have been lost to follow up or died prior to one year or have not yet had a full year to elapse in calendar time, similar data will be collected at the point in time at the last available patient contact with the physician using information in the record. After approach for informed consent from the patient or next of kin for patients who have died to review the medical record, no interaction with the patient will occur.
Study Overview
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All CLL patients who have previously received Arzerra, whether alive or deceased
- Patients who have either completed the full course of Arzerra therapy or discontinued treatment early
Exclusion Criteria:
- CLL patients newly initiating Arzerra
- Patients having been treated with Arzerra in phase II or phase III clinical trials
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with a diagnosis of CLL
|
Treatment with Arzerra
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Physicians' assessment of response
Time Frame: Approximately one-year post-drug initiation or at the last available patient contact with the physician
|
Physicians' assessment of response to include one or more of the following: CR, MRD status, incomplete CR, PR nodular, Stable Disease, Refractory/Progressive disease
|
Approximately one-year post-drug initiation or at the last available patient contact with the physician
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events
Time Frame: Approximately one-year post-drug initiation or at the last available patient contact with the physician
|
Approximately one-year post-drug initiation or at the last available patient contact with the physician
|
Progression-free survival
Time Frame: Approximately one-year post-drug initiation or at the last available patient contact with the physician
|
Approximately one-year post-drug initiation or at the last available patient contact with the physician
|
Overall survival
Time Frame: Approximately one-year post-drug initiation or at the last available patient contact with the physician
|
Approximately one-year post-drug initiation or at the last available patient contact with the physician
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 114429
- WEUSRTP4799 (Other Identifier: GSK)
- EPI40635 (Other Identifier: GSK)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukaemia, Lymphocytic, Chronic
-
AstraZenecaCLL ConsortiumCompletedB Cell Lymphomas | 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), | Prolymphocytic Leukaemia (PLL)United States
-
GlaxoSmithKlineCompletedLeukaemia, Lymphocytic, ChronicKorea, Republic of, Japan
-
Novartis PharmaceuticalsCompletedChronic Lymphocytic Leukemia (CLL) | Leukaemia, Lymphocytic, ChronicUnited States, Belgium, Italy, Greece, Russian Federation, Spain, Poland, Czech Republic
-
GlaxoSmithKlineCompletedLeukaemia, Lymphocytic, ChronicJapan
-
GlaxoSmithKlineGenmabCompletedLeukaemia, Lymphocytic, ChronicSweden
-
GlaxoSmithKlineCompletedLeukaemia, Lymphocytic, ChronicAustralia, United States, New Zealand
-
Novartis PharmaceuticalsCompletedLeukaemia, Lymphocytic, ChronicIndia, United Kingdom, Netherlands, Canada, Germany, Greece, Italy, Poland, Russian Federation, Spain, Taiwan, Thailand, United States, Brazil, Bulgaria, Mexico, Romania, Ukraine
-
Novartis PharmaceuticalsTerminatedLeukaemia, Lymphocytic, ChronicSpain, United States, Belgium, India, United Kingdom, Netherlands, Czechia, Germany, Greece, Italy, Russian Federation, Sweden, Canada, Ireland, Poland, France, Brazil
-
Gilead SciencesCompletedChronic Lymphocytic LeukaemiaUnited Kingdom, Ireland
-
GlaxoSmithKlineCompletedLeukaemia, Lymphocytic, ChronicUnited States, United Kingdom
Clinical Trials on Arzerra
-
M.D. Anderson Cancer CenterGlaxoSmithKlineActive, not recruitingLymphoma | LeukemiaUnited States
-
SCRI Development Innovations, LLCGlaxoSmithKline; NovartisCompletedChronic Lymphocytic LeukemiaUnited States
-
Tang-Du HospitalHenan Provincial People's HospitalRecruiting
-
M.D. Anderson Cancer CenterGlaxoSmithKlineCompletedChronic Lymphocytic LeukemiaUnited States
-
Grupo Español de Linfomas y Transplante Autólogo...Completed
-
Grupo Español de Linfomas y Transplante Autólogo...Completed
-
Grupo Espanol de trasplantes hematopoyeticos y...GlaxoSmithKlineCompleted
-
Fondazione Italiana Linfomi ONLUSCompletedFollicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3AItaly
-
GlaxoSmithKlineCompletedLeukaemia, Lymphocytic, ChronicAustralia, United States, New Zealand
-
UNC Lineberger Comprehensive Cancer CenterGlaxoSmithKlineWithdrawnLymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, B-Cell, Marginal Zone | Lymphoma, Low-Grade | Lymphoma, Intermediate-Grade